Such breakthroughs hold out the prospect of substantial improvements in the productivity
of early stage drug screening. Of course, Atomwise’s technology (and that of other companies
leveraging artificial intelligence to advance drug discovery or medical diagnosis) is still at an
early stage: though their initial results seem to be promising, no new drugs have actually come
to market using these new approaches. But whether or not Atomwise delivers fully on its
promise, its technology is representative of the ongoing attempt to develop a new innovation
“playbook”, one that leverages large datasets and learning algorithms to engage in precise
prediction of biological phenomena in order to guide design effective interventions. Atomwise,
for example, is now deploying this approach to the discovery and development of new pesticides
and agents for controlling crop diseases.
You are viewing a single comment's thread from: